

Study: **ENGOT-en11 / KEYNOTE-B21**

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053 / MK3475-B21)

MaNGO Sites:

Prov	City	Site	Principal Investigator	Active
BS	Brescia	Spedali Civili	Germana Tognon	Yes
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo *	Yes
PD	Padova	Istituto Oncologico Veneto	Pierfranco Conte	Yes

***MaNGO Principal Investigator**